Citations

Clear

4510 citation(s) found for "Scott, C".

International, Multispecialty Expert Consensus on Nomenclature for Facial Paralysis
Oyer, Samuel L. , Baptista, Rachel, Boahene, Kofi , Byrne, Patrick J., Chuang, David Chwei‐Chin , Dey, Jacob K. , Diels, Jackie , Hadlock, Tessa A. , Hetzler, Laura , Klebuc, Michael, Labbé, D., Loyo, Myriam , Miller, Matthew Q. , Pepper, Jon‐Paul , Rozen, Shai M. , Snyder‐Warwick, Alison K. , Stephan, Scott J., Tzafetta, Kallirroi , Azizzadeh, Babak , Byrne, Patrick , Dey, Jacob K , Lassaletta, Luis , Loyo, Myriam , Miller, Matthew Q , Pepper, Jon-Paul , Rozen, Shai , Azizzadeh, Babak , Borschel, Gregory Howard , Guerreschi, Pierre , Gur, Eyal , Kim, Jennifer , Mardini, Samir

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | September 30, 2025 | Volume: 27 | Issue: 5 | Pages: 408-415

10.1177/26893614251363957 | PMID 40876002 Get It

Background: Variable terminology is used in the literature to describe facial synkinesis and hypertonicity following incomplete recovery from facial paralysis and its associated medical and surgical treatments. Study Objectives: Establish a nomenclature consensus for this condition among a group of facial nerve experts. Design Type: Consensus study. Methods: Using modified Delphi methodology, an international, multidisciplinary group of facial nerve experts reviewed the terminology for the name of the clinical condition and treatments of interest. Online surveys and a virtual discussion were performed to establish consensus, defined a priori as agreement by 80% of the group. Results: Twenty-five facial nerve experts established consensus after three Delphi rounds. Consensus terminology for the condition is “facial synkinesis” with 84% agreement. Medical treatment is termed “chemodenervation” with 100% agreement. Surgical treatments including “selective facial neurectomy,” “selective facial neurotomy,” “selective facial myectomy,” and “selective facial myotomy,” were defined and reached agreement of 100%. Conclusions: This international group of facial nerve experts has recommended standardized nomenclature for the condition of facial synkinesis and its various treatments. While “facial synkinesis” reached consensus as the preferred term, some experts noted it may insufficiently describe the full clinical spectrum, which includes muscle hypertonicity, weakness, and spontaneous twitching.
Extracellular matrix alterations in chronic ischemic cardiomyopathy revealed by quantitative proteomics
Buck, Kevin M. , Gregorich, Zachery R. , Gao, Zhan , Price, Scott J., Rogers, Holden T. , Mann, Morgan , Aballo, Timothy J. , Chapman, Emily A. , Perciaccante, Andrew J. , Lei, Ienglam , Tang, Paul C. , Ge, Ying Ping

Mayo Clinic

JCI Insight | September 30, 2025 | Volume: 10 | Issue: 21 | Pages: No page available

10.1172/jci.insight.196933 | PMID 41026521 Get It

Ischemic cardiomyopathy (ICM) is a leading cause of heart failure characterized by extensive remodeling of the cardiac extracellular matrix (ECM). While initially adaptive, ECM deposition following ischemic injury eventually turns maladaptive, promoting adverse cardiac remodeling. The strong link between the extent of fibrosis and adverse clinical outcomes has led to growing interest in ECM-targeted therapies to prevent or reverse maladaptive cardiac remodeling in ICM; yet, the precise composition of the ECM in ICM remains poorly defined. In this study, we employed sequential protein extraction enabled by the photocleavable surfactant Azo to enrich ECM proteins from left ventricular tissues of patients with end-stage ICM and nonfailing donor hearts. High-resolution mass spectrometry–based quantitative proteomics identified and quantified over 6,000 unique protein groups, including 315 ECM proteins. We discovered significant upregulation of key ECM components, particularly glycoproteins, proteoglycans, collagens, and ECM regulators. Notably, LOXL1 , FBLN1 , and VCAN were among the most differentially expressed. Functional enrichment analyses revealed enhanced TGFB signaling, integrin-mediated adhesion, and complement activation in ICM tissues, suggesting a feedback loop driving continued ECM deposition in the end-stage failing heart. Together, our findings provide a comprehensive proteomic landscape of ECM alterations in the end-stage ICM myocardium and identify promising molecular targets for therapeutic intervention.
Hemorrhagic Ovarian Cysts Over 50 mm
Zhu, Alan , Sugi, Mark , Young, Scott W. , Morgan, Tara A. , Patel, Maitray D , Sugi, Mark D , Young, Scott W , Patel, Maitray D.

Mayo Clinic

Journal of Ultrasound in Medicine | September 30, 2025 | Volume: 45 | Issue: 3 | Pages: 497-507

10.1002/jum.70081 | PMID 41024600 Get It

Objectives Evaluate the value of ultrasound specialist assessment of ovarian masses over 50 mm with sonograms interpreted as possible hemorrhagic ovarian cysts (HOC). Methods Retrospective review of consecutive endovaginal pelvic US reports of premenopausal women at one organization identified adnexal masses over 50 mm maximum diameter designated as possibly being HOC (large HOC). Four ultrasound specialists reviewed studies, scoring two assessments as true or false: 1) US features are most consistent with either an ovarian hemorrhagic cyst (HOC) or endometrioma; 2) If assessment 1 was true, the mass meets O‐RADS criteria of classic HOC except for size. Results A total of 457 of 51,305 women (0.9%) had reports indicating possible large HOC. For 366 patients with established outcomes, 225 (61.5%) had a large HOC (87.1% ≤ 70 mm). Assessment 1 was true for 318 patients; outcomes showed 224 (70.4%) HOC, 89 (28.0%) endometriomas, 4 (1.3%) TOAs, and 1 (0.3%) cystadenoma. Assessment 1 was false for 48 patients; outcomes showed 1 (2.1%) HOC, 1 (2.1%) endometrioma, 6 (12.5%) other non‐neoplastic cysts, 33 (68.8%) benign neoplasms, 5 (10.4%) borderline tumors, and 2 (4.2%) high‐grade malignancies. The decrease in neoplasms and malignancies with true assessment 1 was significant ( p < .001). Assessment 2 was true for 190 patients (180 [94.7%] HOC, 9 [4.7%] endometrioma, 1 [0.5%] cystadenoma), false for 128 patients (44 [34.4%] HOC, 80 [62.5%] endometrioma, and 4 [3.1%] TOA) ( p < .001), and not applicable for 48 patients. Conclusions Ultrasound specialist review of adnexal masses designated as a possible large HOC adds value since over 10% are neoplasms (nearly 2% malignant). Ultrasound specialist assessment can expedite additional imaging or intervention when necessary and obviate follow‐up when HOC features are typical.
Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm
Cherukuri, Swathi Priya , Kaur, Anmolpreet , Goyal, Bipasha, Kukunoor, Hanisha Reddy , Sahito, Areesh Fatima, Sachdeva, Pratyush , Yerrapragada, Gayathri, Poonguzhali, E. , Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Richard, Samuel, Venkatesaprasath, Shakthidevi Pallikaranai, Karuppiah, Shiva Sankari, Iyer, Vivek , Helgeson, Scott A. , Arunachalam, Shivaram P. , Kaur, Anmolpreet , Natarajan, Thangeswaran , Pallikaranai Venkatesaprasath, Shakthidevi, Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Sahito, Areesh Fatima , Natarajan, Thangeswaran

Mayo Clinic

Cancers | September 29, 2025 | Volume: 17 | Issue: 19 | Pages: 3165

10.3390/cancers17193165 | PMID 41097693 Get It

Background: Lung cancer remains the leading cause of cancer-related mortality globally, largely due to delayed diagnosis in its early stages. While conventional diagnostic tools like low-dose CT and tissue biopsy are routinely used, they suffer from limitations including invasiveness, radiation exposure, cost, and limited sensitivity for early-stage detection. Liquid biopsy, a minimally invasive alternative that captures circulating tumor-derived biomarkers such as ctDNA, cfRNA, and exosomes from body fluids, offers promising diagnostic potential—yet its sensitivity in early disease remains suboptimal. Recent advances in Artificial Intelligence (AI) and radiomics are poised to bridge this gap. Objective: This review aims to explore how AI, in combination with radiomics, enhances the diagnostic capabilities of liquid biopsy for early detection of lung cancer and facilitates personalized monitoring strategies. Content Overview: We begin by outlining the molecular heterogeneity of lung cancer, emphasizing the need for earlier, more accurate detection strategies. The discussion then transitions into liquid biopsy and its key analytes, followed by an in-depth overview of AI techniques—including machine learning (e.g., SVMs, Random Forest) and deep learning models (e.g., CNNs, RNNs, GANs)—that enable robust pattern recognition across multi-omics datasets. The role of radiomics, which quantitatively extracts spatial and morphological features from imaging modalities such as CT and PET, is explored in conjunction with AI to provide an integrative, multimodal approach. This convergence supports the broader vision of precision medicine by integrating omics data, imaging, and electronic health records. Discussion: The synergy between AI, liquid biopsy, and radiomics signifies a shift from traditional diagnostics toward dynamic, patient-specific decision-making. Radiomics contributes spatial information, while AI improves pattern detection and predictive modeling. Despite these advancements, challenges remain—including data standardization, limited annotated datasets, the interpretability of deep learning models, and ethical considerations. A push toward rigorous validation and multimodal AI frameworks is necessary to facilitate clinical adoption. Conclusion: The integration of AI with liquid biopsy and radiomics holds transformative potential for early lung cancer detection. This non-invasive, scalable, and individualized diagnostic paradigm could significantly reduce lung cancer mortality through timely and targeted interventions. As technology and regulatory pathways mature, collaborative research is crucial to standardize methodologies and translate this innovation into routine clinical practice.
Mini‐lattice radiation therapy: A treatment planning approach to miniaturize spatially fractionated lattice radiation therapy using a clinical linear accelerator
Hara, Daiki , Abou‐Mourad, Houssam, Thull, Jack C., Laack, Nadia N., Self, Chelsea, Fernandez‐Rodriguez, Alfredo , Prezado, Yolanda , Tseung, Hok Seum Wan Chan, Breen, William G. , Mutter, Robert W. , Antolak, John A. , Tseung, Hok Seum W C, Lester, Scott C. , Park, Sean S. , Grams, Michael P.

Mayo Clinic

Medical Physics | September 29, 2025 | Volume: 52 | Issue: 10 | Pages: No page available

10.1002/mp.70027 | PMID 41016844 Get It

Abstract Background Spatially fractionated radiation therapy (SFRT) is a technique that delivers heterogenous dose distributions consisting of alternating regions of high dose “peaks” and low dose “valleys”. Current delivery methods for SFRT using megavoltage x‐rays usually treat large and bulky tumors with brass grid or volumetric modulated arc therapy (VMAT) lattice techniques. The size and spacing of high dose regions in these approaches are typically on the order of centimeters. However, multiple studies have suggested that decreasing these dimensions may improve the therapeutic ratio. Furthermore, a more compact approach to SFRT would allow for a greater number of high dose regions within the tumor, as well as application to smaller and more irregularly shaped targets thereby increasing the number of patients that could benefit from SFRT. Purpose This study describes the commissioning and first patient treatment using mini‐lattice radiation therapy (MLRT). MLRT uses a clinical linear accelerator and decreases the size and spacing of standard lattice SFRT by using individual multileaf collimator (MLC) leaves to deliver 5 mm wide high dose regions. Methods MLRT plans were created in the Varian Eclipse treatment planning system for a Varian Truebeam equipped with Millennium 120 MLCs. MLRT uses 6 MV Flattening Filter Free high dose rate and the width of individual MLCs to define 5 mm by 5 mm openings separated by closed MLCs to deliver alternating opened and blocked regions. Dynamic conformal arcs were used to conform MLCs to 4 mm spherical mini‐lattice structures in the gross tumor volume (GTV). A MLRT‐specific beam model was commissioned to accurately model the small MLRT fields. Film measurements were performed to assess the accuracy of MLRT plans calculations. Plans for seven treatment sites in different parts of the body for retrospective patient candidates were created with varying numbers of mini‐lattices and separation distances to assess the impact of varying these parameters on treatment dose metrics. MLRT was used for the first time to treat a patient with two fractions of MLRT. Results The AcurosXB calculation algorithm with modified x and y spot sizes, dosimetric leaf gap, transmission factor, and output factor table was used to generate a beam model for accurate MLRT calculations. The MLRT‐specific beam model resulted in gamma passing rates (1%/0.5 mm criteria) of 90%–99% for retrospective patient MLRT film measurements. Dose volume histogram statistics, equivalent uniform dose, and mean dose showed a higher number of mini‐lattices with smaller separation increased the dose to the GTV and surrounding tissue. Separation distances between mini‐lattices did not impact plan heterogeneity as measured by D10%/D90%. The first patient treated with the MLRT technique reported pain relief, had stable disease, and no acute toxicities following both fractions. Conclusions MLRT is feasible using clinical linear accelerators and existing radiation oncology infrastructure. It enables targeting smaller tumors with SFRT, allows for a greater number of high dose regions within the target compared to standard VMAT lattice techniques, and may be a useful technique for challenging treatment scenarios.
Stranded in the emergency department: an analysis of boarding trends in older adults in the United States
Sifnugel, Natalia, Jeffery, Molly M. , Grogan, Elyssa F L , Sangal, Rohit B. , Carr, Brendan M. , Cruz, Daniel S. , Dresden, Scott M. , Gettel, Cameron J. , Iscoe, Mark , Skains, Rachel M. , Hwang, Ula , Jeffery, Molly Moore , Dresden, Scott , Venkatesh, Arjun , Hwang, Ula , Skains, Rachel M , Venkatesh, Arjun K.

Mayo Clinic

Health Affairs Scholar | September 26, 2025 | Volume: 3 | Issue: 10 | Pages: No page available

10.1093/haschl/qxaf187 | PMID 41143086 Get It

Abstract Introduction The rapidly ageing population and multimorbidity are associated with increased emergency department (ED) visits by older adults. In the ED, older adults have higher risk of hospitalization, functional and cognitive decline, and mortality. Boarding, holding admitted patients in the ED awaiting a hospital bed, exacerbates these negative outcomes, which disproportionately affect older adults. Methods We conducted a cross-sectional analysis to investigate US boarding trends by age using clinical administrative data from 5 health systems and publicly available NHAMCS data from 2018 to 2024. Results Boarding ≥3 h in the ED has increased across diverse hospital types, with oldest adults (85+) facing the greatest risk (System 4: IRR [95% CI] = 1.18 [1.15-1.20], System 5: IRR [95% CI] = 1.20 [1.17-1.23], System 3 [Community Hospital]: IRR [95% CI] = 1.25 [1.19-1.33]). These results were recapitulated at the national level in NHAMCS (IRR [95% CI] = 1.30 [1.05-1.61]). Discussion The trend of increased boarding has serious implications for patients, caregivers, and health systems. The 2025 CMS Age-Friendly Hospital Measure offers opportunities to improve processes and procedures to mitigate the negative effects of hospital boarding on older patients. We highlight opportunities to address this challenge, including ongoing quality improvement initiatives, bed prioritization algorithms, and alternate admission pathways.
Sinonasal Tract Osteochondromyxoma: An Underrecognized Tumor Easily Mistaken for Nasal Chondromesenchymal Hamartoma
Bishop, Justin A., Alani, Ali, Fernandes, Igor Lima , Bacchi, Carlos E. , Klink, Daniel F., Marshall, Carrie B. , Folpe, Andrew L. , Bishop, Justin A. , Baumhoer, Daniel

Mayo Clinic

No container title available | September 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7594659/v1 Get It

Abstract Matrix-producing tumors of the sinonasal region are diagnostically challenging, with a large number of similar-appearing neoplasms having different prognoses, treatment strategies, and genetic syndrome associations. Osteochondromyxoma (OCM) is a very rare tumor known to be associated with Carney complex. Since its initial description in 2001, fewer than 20 cases have been reported, with the sinonasal tract being an apparently favored site. Herein we describe 6 new cases of sinonasal OCM.OCM cases with available slides were retrieved from the surgical pathology files of the authors’ practices. The tumors arose in 4 boys and 2 girls, ranging from 4 to 17 years (mean, 9.5 years). All presented with nasal obstruction and a mass. Radiologically the tumors presented as indolent-appearing, heterogeneous, calcified, expansile masses. Histologically the tumors all consisted of bland, normochromatic spindled to stellate cells in a myxoid to collagenized stroma, with variable amounts of cartilage and bone formation. Mitotic activity was very low and necrosis was absent. All demonstrated complete loss of PRKAR1A expression by immunohistochemistry. Of these 6 cases, 3 had been originally diagnosed as nasal chondromesenchymal hamartomas, and one as osteosarcoma. Treatment and follow up information were available for 5 patients: all were treated with surgery, with one also receiving chemotherapy after an initial osteosarcoma diagnosis. At the time of last clinical follow-up, all 5 patients were alive, one with residual disease. No patient was known to have other stigmata of Carney complex.Although rare, OCM preferentially occurs in the sinonasal tract, and therefore may be encountered by head and neck pathologists. Given their predilection for young patients and overlapping morphologic features, OCM are easily misdiagnosed as other matrix-forming sinonasal tumors, especially nasal chondromesenchymal hamartoma. Immunohistochemical demonstration of PRKAR1A loss is valuable for confirming an OCM diagnosis, which should prompt clinical investigation for the possibility of Carney complex.
Early Removal of Ureteral Stents When Attached to the Foley Catheter in Living Donor Kidney Transplant Recipients Reduces Urinary Tract Infections
Lam, Jenny , Mahgoub, Mohammed, Kesik, Esma, Smith, Byron H. , Ovdat, Esther , Rebolledo, Patricia , Bunn, Weslyn, Reddy, Kunam S. , Perry, Dana K. , Prieto, Mikel , Nyberg, Scott L. , Elali, Ibrahim, Kesik, Esma , Smith, Byron , Jadlowiec, Caroline , Mao, Shennen, Perry, Dana, Bentall, Andrew , Schinstock, Carrie , Nyberg, Scott, Stegall, Mark D , Elali, Ibrahim , Jadlowiec, Caroline C. , Mao, Shennen A. , Bentall, Andrew , Schinstock, Carrie A. , Stegall, Mark D.

Mayo Clinic

Clinical Transplantation | September 24, 2025 | Volume: 39 | Issue: 10 | Pages: No page available

10.1111/ctr.70329 | PMID 40988593 Get It

ABSTRACT Background Ureteral stents are commonly placed during kidney transplantation (KT) to mitigate urologic complications. The objective of this study was to compare clinical outcomes in KT recipients with either early stent removal when attached to the Foley catheter or late removal via cystoscopy when unattached. Methods We conducted a multi‐center retrospective analysis of consecutive living donor KT patients (8/18/21‐4/21/23) stratified into Foley‐attached and unattached stent groups. Outcomes assessed were ureteral stricture, urine leaks, UTIs at 90 days and allograft failure and BKV DNAemia (BK virus DNAemia) at 1 year. Data are reported as mean and standard deviation. Results Among 247 patients with attached and 260 with unattached stents, baseline demographics (age, sex, diabetes) were similar between groups. There was a difference in race (87.9% vs. 77.8% Caucasian; p = 0.004). Foley catheters remained longer in the attached group (3.7 ± 1.8 vs. 3.0 ± 2.0 days; p < 0.001), but stents were removed earlier (3.7 ± 1.8 vs. 21.9 ± 4.7 days; p < 0.001). Comparing attached versus unattached, there were no differences in ureteral stricture (0.4% vs. 1.5%; p = 0.197), urine leak (0.8% vs. 0.4%; p = 0.533), BKV DNAemia (17.7% vs. 16.9%; p = 0.616), or allograft failure (0% vs. 0.8%; p = 0.167). However, UTI incidence by 90 days was lower in the attached group (5.7% vs. 11.9% p = 0.013). Induction therapy differed significantly between groups, with Alemtuzumab more common in the unattached group (58.1% vs. 19.4%, p < 0.001), Basiliximab more common in the attached group (43.3% vs. 35.0%, p < 0.001), and Thymoglobulin more common in the attached group (36.0% vs. 6.9%, p < 0.001). Baseline steroid use was higher in the unattached group (81.9% vs. 57.9%, p < 0.001). Conclusion Early stent removal via connection to the Foley catheter had similarly low rates of ureteral complications while reducing urinary tract infections and avoiding cystoscopic removal.
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study
Hussain, Yessar, Malhotra, Saurabh , Sperry, Brett W. , Shu, Francy , Ananthasubramaniam, Karthikeyan , Desai, Urvi , Egolum, Ugochukwu , Fernandez, Joel , Freimer, Miriam , Mauricio, Elizabeth A. , Quan, Dianna , Small, Roy S., Capocelli, Kelley E. , Roblin, Steven, Bender, Shaun , Jay, Patrick Y. , Yureneva, Elena, Zolty, Ronald , Mauricio, Elizabeth A. , Capocelli, Kelley , Sperry, Brett W

Mayo Clinic

Annals of Medicine | September 20, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2537347 | PMID 40974604 Get It

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, Ioannis , Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , VanDommelen, Kyle, Gupta, Garima , Akce, Mehmet , Yang, Ju Dong , Chen, Pin‐Jung , Naleid, Nikolas , Peterson, Nicole , Sahai, Vaibhav , Halfdanarson, Thorvardur, Kankeu, Lionel Fonkoua, Washburn, Leslie, Conboy, Caitlin B. , Goenka, Ajit H. , Thompson, Scott A. , Ahn, Daniel H. , Jatoi, Aminah , Marell, Paulina, Gile, Jennifer , Yang, Ju Dong , Sahai, Vaibhav , Jin, Zhaohui , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A, Goenka, Ajit, Starlinger, Patrick , Roberts, Lewis, Jatoi, Aminah , Ou, Fang-Shu , Tran, Nguyen , Conboy, Caitlin B , Kamath, Suneel Deepak , Mahipal, Amit , Wee, Wen , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Torbenson, Michael , Thompson, Scott, Venkatesh, Sudhakar K. , Starlinger, Patrick , Roberts, Lewis R. , Gores, Gregory J. , Babiker, Hani M. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , McWilliams, Robert R. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf286 | PMID 40973475 Get It

Abstract Background Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. Methods We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteristics. Results Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P &lt; .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P &lt; .001). Conclusions In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.